Theriva Biologics Inc.

13F holders, Q1 2024 (March 31)
24holders
2famous investors
$1.73avg. 13F price*

At the end of Q1 2024, 24 institutions reported holding Theriva Biologics Inc. in their 13F filings. The largest holders were SageView Advisory Group, LLC ($1.0M), Vanguard Group Inc. ($106K) and BlackRock Inc. ($89K). 2 famous investors held it, including Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio) and Ken Griffin (0.0% of Citadel Advisors's portfolio).

Company
Theriva Biologics Inc.
CUSIP
87164U409
Latest filing quarter
Q3 2024

History

Number of 13F holders

0510152025 Q1 2024: 24Q1 2024Q2 2024: 22Q2 2024Q3 2024: 1Q3 2024

Total Exit/New Position Q1 2024

InstitutionsTotal Value
New Positions4$1.0M
Exits4$54K

Ownership 24 holders

SageView Advisory Group, LLC 0.05% New 10,429 $1.0M
Vanguard Group Inc. 0.00% Reduce -38.5% 225,271 $106K
BlackRock Inc. 0.00% Reduce -0.5% 189,181 $89K
Geode Capital Management, LLC 0.00% No change 141,168 $66K
Renaissance Technologies 0.00% Add +15.7% 68,510 $32K
State Street Corp. 0.00% No change 48,691 $23K
Northern Trust Corp. 0.00% No change 26,599 $12K
Citadel Advisors 0.00% Reduce -57.4% 24,679 $12K
Two Sigma Securities, LLC 0.00% New 21,273 $10K
Charles Schwab Investment Management Inc. 0.00% No change 13,566 $6K
Lincoln National Corp. 0.00% No change 11,000 $5K
Blair William & Co. 0.00% No change 10,153 $5K
Iron Horse Wealth Management, LLC 0.00% New 365 $171
IFP Advisors, Inc 0.00% No change 296 $139
Wells Fargo & Company 0.00% Add +0.9% 233 $109
Tower Research Capital LLC (TRC) 0.00% No change 145 $68
Towne Trust Company, N.A 0.00% New 100 $47
Osaic Holdings, Inc. 0.00% No change 47 $21
Morgan Stanley 0.00% Reduce -97.1% 15 $7
Steward Partners Investment Advisory, LLC 0.00% No change 14 $7
FMR LLC 0.00% Add +11.1% 10 $5
Bank of America Corp. 0.00% No change 6 $3
UBS Group AG 0.00% No change 3 $1
Royal Bank of Canada 0.00% Add +28.6% 9 $0

"% of holder's portfolio" is THERIVA BIOLOGICS INC's weight in each manager's 13F, not the share of Theriva Biologics Inc. the manager owns.